Clinical Trial Update: This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated empagliflozin in chronic heart failure with preserved ejection fraction (HFpEF), focusing on 6-minute walk test distance and HF sympto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2020-12-08